Impact Factor 6.429

The 5th most cited journal in Immunology

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2018.00619

Anti-TGFβ IgG elicits a dual effect on calcium oxalate crystallization and progressive nephrocalcinosis-related chronic kidney disease

 Stefanie Steiger1*,  Julia F. Grill1,  Qiuyue Ma1, Tobias Bäuerle2, Jutta Jordan2,  Michaela Smolle3, Claudia Böhland4,  Maciej Lech1 and  Hans-Joachim Anders1
  • 1Division of Nephrology, Klinikum der Universität München, Germany
  • 2Institute of Radiology, Universitätsklinikum Erlangen, Germany
  • 3Biomedizinisches Centrum, Ludwig-Maximilians-Universität München, Germany
  • 4Department of Radiation Oncology, Ludwig-Maximilians-Universität München, Germany

Crystallopathies are a heterogeneous group of diseases caused by intrinsic or environmental microparticles or crystals, promoting tissue inflammation and scarring. Certain proteins interfere with crystal formation and growth, e.g. with intrarenal calcium oxalate (CaOx) crystal formation, a common cause of kidney stone disease or nephrocalcinosis-related chronic kidney disease (CKD). We hypothesized that immunoglobulins can modulate calcium oxalate microcrystal formation and crystal growth and that therefore, biological IgG-based drugs designed to specifically target disease modifying proteins would elicit a dual effect on the outcome of calcium oxalate-related crystallopathies.
Indeed, both the anti-TGFβ IgG and control IgG1 antibody impaired CaOx crystallization in vitro, and decreased intrarenal CaOx crystal deposition and subsequent CKD in mice on an oxalate-rich diet compared to oxalate-fed control mice. However, the TGFβ-specific IgG antibody showed nephroprotective effects beyond those of control IgG1 and substantially reduced interstitial fibrosis as indicated by magnetic resonance imaging, silver and α-SMA staining, RT-qPCR, and flow cytometry for pro-fibrotic macrophages. Suppressing interstitial fibrosis slowed the decline of GFR compared to treatment with control IgG1 (slope of m=-8.9 vs. m=-14.5 µl/min/100g BW/day, Δ=38.3%), an increased GFR at the end of the study (120.4 vs. 42.6 µl/min/100g BW, Δ=64.6%), and prolonged end stage renal disease (ESRD)-free renal survival by 10 days (Δ=38.5%). Delayed onset of anti-TGFβ IgG from day 7 was no longer effective. Our results suggest that biological drugs can elicit dual therapeutic effects on intrinsic crystallopathies, such as anti-TGFβ IgG antibody treatment inhibits CaOx crystallization as well as interstitial fibrosis in nephrocalcinosis-related CKD.

Keywords: Calcium Oxalate, Crystallization, transforming growth factor β, Fibrosis, Nephrocalcinosis, Chronic Kidney Disease

Received: 24 Jan 2018; Accepted: 12 Mar 2018.

Edited by:

Philippe Saas, INSERM UMR1098 Interactions Hôte-Greffon-Tumeur & Ingénierie Cellulaire et Génique, France

Reviewed by:

Joseph I. Shapiro, Marshall University, United States
Yufeng Huang, University of Utah, United States  

Copyright: © 2018 Steiger, Grill, Ma, Bäuerle, Jordan, Smolle, Böhland, Lech and Anders. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Stefanie Steiger, Klinikum der Universität München, Division of Nephrology, Munich, Germany,